Elite Pharmaceuticals (ELTP)
(Delayed Data from OTC)
$0.20 USD
+0.01 (2.83%)
Updated Aug 23, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Elite Pharmaceuticals Inc falls in the month of March.
All items in Millions except Per Share data.
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 7 | 8 | 9 | 3 | 1 |
Receivables | 19 | 3 | 3 | 4 | 4 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 13 | 10 | 7 | 5 | 4 |
Other Current Assets | 1 | 1 | 1 | 0 | 1 |
Total Current Assets | 40 | 22 | 19 | 12 | 10 |
Net Property & Equipment | 10 | 10 | 6 | 7 | 7 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 22 | 2 | 2 | 0 | 0 |
Intangibles | 6 | 6 | 7 | 7 | 7 |
Deposits & Other Assets | 1 | 0 | 1 | 1 | 0 |
Total Assets | 84 | 41 | 35 | 26 | 25 |
Liabilities & Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Notes Payable | 4 | 0 | 0 | 0 | 1 |
Accounts Payable | 3 | 2 | 1 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 1 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 5 | 5 | 5 | 4 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 13 | 8 | 7 | 6 | 9 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 3 | 4 | 1 | 2 | 2 |
Non-Current Capital Leases | 1 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 6 | 1 | 1 | 2 | 4 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 26 | 12 | 10 | 10 | 14 |
Shareholders Equity | 3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 14 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 173 | 165 | 165 | 164 | 150 |
Retained Earnings | -116 | -137 | -140 | -149 | -154 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 58 | 29 | 25 | 16 | 11 |
Total Liabilities & Shareholder's Equity | 84 | 41 | 35 | 26 | 25 |
Total Common Equity | 58 | 29 | 25 | 16 | -3 |
Shares Outstanding | 1,068.20 | 1,013.90 | 1,011.20 | 1,009.10 | 840.40 |
Book Value Per Share | 0.05 | 0.03 | 0.02 | 0.02 | 0.00 |
Fiscal Year End for Elite Pharmaceuticals Inc falls in the month of March.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 8 | 7 | 6 | 9 | 9 |
Receivables | 20 | 19 | 16 | 11 | 6 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 14 | 13 | 14 | 15 | 11 |
Other Current Assets | 0 | 1 | 1 | 0 | 1 |
Total Current Assets | 43 | 40 | 37 | 35 | 27 |
Net Property & Equipment | 11 | 10 | 10 | 10 | 10 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 22 | 22 | 20 | 19 | 2 |
Intangibles | 7 | 6 | 6 | 6 | 6 |
Deposits & Other Assets | 1 | 1 | 0 | 0 | 0 |
Total Assets | 88 | 84 | 75 | 71 | 47 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 4 | 0 | 4 | 4 |
Accounts Payable | 3 | 3 | 3 | 4 | 2 |
Current Portion Long-Term Debt | 4 | 0 | 4 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 6 | 5 | 12 | 11 | 6 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 14 | 13 | 19 | 19 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 3 | 3 | 3 | 3 | 4 |
Non-Current Capital Leases | 1 | 1 | 0 | 0 | 0 |
Other Non-Current Liabilities | 9 | 6 | 3 | 1 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 30 | 26 | 28 | 26 | 16 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1 | 1 | 1 | 1 | 1 |
Capital Surplus | 173 | 173 | 165 | 165 | 165 |
Retained Earnings | -116 | -116 | -120 | -120 | -135 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 58 | 58 | 46 | 45 | 30 |
Total Liabilities & Shareholder's Equity | 88 | 84 | 75 | 71 | 47 |
Total Common Equity | 58 | 58 | 46 | 45 | 30 |
Shares Outstanding | 1,068.20 | 1,068.20 | 1,017.70 | 1,013.90 | 1,013.90 |
Book Value Per Share | 0.05 | 0.05 | 0.05 | 0.04 | 0.03 |